Kevin Conroy: JAMA Oncology publication confirms Oncotype DX test reliability across racial and ethnic groups

Kevin Conroy, Chairman and CEO at Exact Sciences, shared a post on LinkedIn:

“An important new comprehensive review published in JAMA Oncology confirms that the Oncotype DX test provides accurate information to help guide breast cancer treatment decisions regardless of race or ethnicity.

Precision medicine should benefit everyone. This growing body of evidence reinforces the trust physicians and patients place in the Oncotype DX test and the critical role it plays in delivering more informed, individualized care.”